drugset
drugset / Trial / NCT04012099

the Hypertrophic Scar Prevention of BMT101.

NCT04012099 ↗

Phase 2 Terminated 20 enrolled Hugel
Non-randomizedSequentialSingle-blindPrevention

Summary

An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial

Timeline

Start
2019-08-21
Primary completion
2023-05-10
Completion
2023-05-10

Outcome

Outcome not reported

Stopped: “Internal reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMT101 Small interfering RNA (siRNA) — Other

Indications

reactive cutaneous fibrous lesion